Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary endpoints in phase 3 trials.The QUANTI studies examined gadoquatrane at a ...

Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025: Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III ...

Bayer presents positive results from phase III study QUANTI CNS of gadoquatrane at ECR 2025: Berlin Thursday, February 27, 2025, 14:00 Hrs [IST] Bayer, a global leader in radiolog ...

Bayer, a global leader in radiology, announced positive results from the Phase III study QUANTI CNS, which evaluated the investigational gadolinium-based contrast agent (GBCA) gadoquatrane in adults ...

QUANTI CNS is part of Bayer’s pivotal QUANTI clinical development program consisting of two multinational Phase III studies in adults as well as a pediatric study. In all studies, gadoquatrane ...

Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III results from the clinical development program QUANTI on investigational MRI contrast ...

Bayer, a global leader in radiology, announced positive results from the Phase III study QUANTI CNS, which evaluated the investigational gadolinium-based contrast agent (GBCA) gadoquatrane in ...

Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III results from the clinical development program QUANTI on investigational MRI contrast agent ...